Testing the Addition of Chemotherapy Drug, Cisplatin, to Usual Radiation Therapy for Patients with Head and Neck Cancer

Study on Radiation and Chemotherapy Treatments for Head and Neck Cancer

Recruiting
18 years - 100 years
All
Phase 2
7 participants needed
1 Location

Brief description of study.

The purpose of this study is to compare two treatment approaches that are currently used after surgery for head and neck cancer. One approach is to administer radiation therapy alone. A second approach is to administer radiation therapy along with the chemotherapy drug, cisplatin.

Detailed description of study

Participants will be assigned to receive either radiation therapy, or radiation therapy along with cisplatin. Both groups will receive treatment for 6 weeks with the doctor following their condition for 10 years after treatment.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Head and Neck Cancer,Cancer,Chemotherapy,Chemo,Radiation
  • Age: 18 years - 100 years
  • Gender: All

Individuals at least 18 years of age with squamous cell carcinoma of the head/neck, that has been surgically removed.

Individuals with recurrent disease or multiple primaries will not be eligible.

Women who are pregnant or breastfeeding will not be eligible.

Updated on 19 Feb 2024. Study ID: 1908611001

This study investigates treatment options for patients with head and neck cancer. The purpose is to compare two different approaches used after surgery. One approach involves using radiation therapy by itself, while the other combines radiation therapy with an investigational chemotherapy medication. Head and neck cancer refers to cancers that develop in the mouth, throat, or other areas in the head and neck region.

Participants will be assigned to one of two study arms. One arm will receive only radiation therapy, and the other will receive both radiation therapy and the investigational chemotherapy medication. The treatment will last for 6 weeks, and doctors will monitor participants' conditions for 10 years after the treatment period.

  • Who can participate: Adults aged 18 and older with squamous cell carcinoma of the head or neck that has been surgically removed are eligible. Individuals with recurrent disease, multiple primaries, or women who are pregnant or breastfeeding are not eligible.
  • Study details: Participants will receive either radiation therapy alone or in combination with the chemotherapy medication cisplatin. A placebo is not used in this study, meaning all participants will receive active treatment.

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact label
Race
Ethnicity
Other language

Default Content Message Here